Mesalamine to Reduce T Cell Activation in HIV Infection

Completed · Phase 4 · Has a placebo group

Conditions studied: HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Lentivirus Infections, Acquired Immunodeficiency Syndrome

In brief

The objective of this study is to determine whether 12 weeks of mesalamine therapy added to a standard HIV treatment decreases systemic immune activation and inflammation in HIV-infected patients, possibly resulting in better recovery of the immune system. The study hypothesis is that decreasing inflammation directly in the gut may decrease both of these potential causes of chronic inflammation, potentially resulting in an immunologic benefit.

Key facts

Study ID

NCT01090102

Run by

University of California, San Francisco

People needed

33

Starts

2010-06-01

Expected to finish

2012-12-01

Last updated by the study team

2014-08-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry.
• Stable antiretroviral therapy for at least 6 months.
• Screening CD4+ T cell count below 350 cells/mm3
• All available CD4+ T cell counts in the last year and at screening <350 cells/mm3
• Screening plasma HIV RNA levels below level of detection (< 40 copies RNA/mL).
• All available plasma HIV RNA levels within past year below the level of detection. Isolated detectable values < 500 c/ml are allowed if HIV RNA levels before and after this time point are undetectable.
• >90% adherence to therapy within the preceding 30 days, as determined by self-report.
• Both male and female subjects are eligible. Females of childbearing potential must have negative pregnancy test at screening and agree to use a double-barrier method of contraception during the study.

You may not qualify if…

• Patients who are intending to modify antiretroviral therapy in the next 24 weeks for any reason.
• Serious illness requiring hospitalization or parental antibiotics within preceding 3 months.
• Exposure to any immunomodulatory drug in the past 16 weeks.
• Active hepatitis C or hepatitis B which will require treatment in the subsequent 24 weeks.
• Screening absolute neutrophil count <1,000 cells/mm3, platelet count <50,000 cells/mm3, Hgb < 8mg/dL
• Pancreatitis or lipase greater than 2 times the upper limit of normal.
• Renal insufficiency with creatinine clearance less than 50 ml/min
• Elevated transaminases greater than 2.5 times the upper limit of normal.
• Evidence of decompensated cirrhosis, heart failure.
• Pregnant or breastfeeding women

Where it is running

• University of California, San Francisco-San Francisco General Hospital — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.